The practicable therapeutic strategy for beta-thalassemia thus involves editing human-peripheral-blood-mobilized CD34+ hematopoietic stem and progenitor cells (HSPSc) by ribonucleoprotein (RNP) electroporation. Here, RNPC3 is linked to Beta-thalassemia.